HealthQuill Pharma
Merck Animal Health will invest $895 million in its US facility to develop novel parasiticides and therapeutics, and expand, filling and freeze dryer capacity, according to a company statement.
Drugs Health Pharma

Merck Animal Health to invest $895 million to expand facility in US

HQ Team May 8, 2025: Merck Animal Health will invest $895 million in its US facility to develop novel parasiticides and therapeutics, and.

Read More
Nuravax Inc. and its partner, the Institute for Molecular Medicine, have received a $3 million grant from the National Institutes of Health to advance its Alzheimer’s vaccine to human trials.
Drugs Health Pharma

Nuravax’s Alzheimer’s vaccine gets $3m grant to enter human trials

HQ Team May 5, 2025: Nuravax Inc. and its partner, the Institute for Molecular Medicine, have received a $3 million grant from the.

Read More
The Global Virus Network warned of an avian influenza currently circulating in the US, spreading to humans and urged enhanced surveillance, biosecurity measures and preparations for a potential human-to-human transmission.
Drugs Health Pharma

Global virologists see potential for an H5N1 pandemic, urge rapid steps

HQ Team May 5, 2025: The Global Virus Network warned of an avian influenza currently circulating in the US, spreading to humans and.

Read More
UK scientists at biotech company Stablepharma have developed a tetanus-diphtheria vaccine that is completely stable at room temperature and does not need to be refrigerated or frozen.
Drugs Health Pharma

UK company starts trial on first ‘fridge-free’ tetanus-diphtheria vaccine

HQ Team May 1, 2025: UK scientists at biotech company Stablepharma Ltd. have developed a tetanus-diphtheria vaccine that is completely stable at room.

Read More
Britain’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved a new under-the-skin injection version of the cancer therapy, nivolumab (Opdivo), offering a quicker administration option for eligible patients than the currently available drip treatment. 
Drugs Medical Pharma

UK regulator clears subcutaneous injection of Bristol Myers for cancers

HQ Team May 1, 2025: Britain’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved a new under-the-skin injection version of the cancer.

Read More
Switzerland’s pharmaceutical company, Novartis AG,  will acquire Regulus Therapeutics for about $1.7 billion to get access to a drug to treat a genetic kidney disease called autosomal dominant polycystic kidney disease.
Drugs Health Pharma

Novartis buys Regulus for $1.7b to grab genetic kidney disease drug

HQ Team April 30, 2025: Switzerland’s pharmaceutical company, Novartis AG,  will acquire Regulus Therapeutics for about $1.7 billion to get access to a.

Read More
Johnson & Johnson’s immune disorder drug has been approved by the US Food and Drug Administration for the treatment of generalised myasthenia gravis (gMG) — a rare disease that causes muscle weakness and affects daily activities like chewing, swallowing, speaking, and breathing.
Drugs Health Pharma

US regulator approves Johnson & Johnson’s immune disorder drug

HQ Team April 30, 2025: Johnson & Johnson’s immune disorder drug has been approved by the US Food and Drug Administration for the.

Read More
British-Swedish pharmaceutical company AstraZeneca Plc. has discontinued its prostate cancer trial as it failed to meet the goal of the radiographic progression-free survival target in test patients.
Drugs Health Pharma

AstraZeneca stops prostate cancer trial, Q1 revenue up 10% to $13.6b

HQ Team April 29, 2025: British-Swedish pharmaceutical company AstraZeneca Plc. has discontinued its prostate cancer trial as it failed to meet the goal.

Read More
Germany’s Merck KGaA, is set to acquire biopharmaceutical company SpringWorks Therapeutics Inc. for $3.9 billion in cash to add rare tumour therapies to its portfolio.
Drugs Medical Pharma

Merck to buy SpringWorks for $3.9b to add rare tumour medicines

HQ Team April 29, 2025: Germany’s Merck KGaA, is set to acquire biopharmaceutical company SpringWorks Therapeutics Inc. for $3.9 billion in cash to.

Read More
Italfarmaco SpA., a privately held Italian pharmaceutical and chemical company, received a recommendation for the conditional marketing in the European Union of an oral drug for Duchenne muscular dystrophy in patients six years or older, who can walk.
Drugs Medical Pharma

Italfarmaco gets conditional marketing nod in EU for DMD drug

HQ Team April 27, 2025: Italfarmaco SpA., a privately held Italian pharmaceutical and chemical company, received a recommendation for the conditional marketing in.

Read More